Double-Blind, randomized, parallel group study on gastrointestinal tolerability of ERL080A vs. mycophenolate mofetil (Cellcept) in renal transplant patients.

Grants and Contracts Details

StatusFinished
Effective start/end date1/1/014/30/02

Funding

  • Novartis (domestic): $2,350.00